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Impact of Cumulative Inflammation, Cardiac Risk Factors, 
and Medication Exposure on Coronary Atherosclerosis 
Progression in Rheumatoid Arthritis
George A. Karpouzas,  Sarah R. Ormseth, Elizabeth Hernandez, and Matthew J. Budoff
Objective. To explore incidence and progression of coronary atherosclerosis and identify determinants in patients 
with rheumatoid arthritis (RA). We specifically evaluated the impact of inflammation, cardiac risk factors, duration of 
medication exposure, and their interactions on coronary plaque progression.
Methods. One hundred one participants with baseline coronary computed tomography angiography findings 
underwent follow- up assessment a mean ± SD of 83 ± 3.6 months after baseline. Plaque burden was reported as 
the segment involvement score (describing the number of coronary segments with plaque) and the segment stenosis 
score (characterizing the cumulative plaque stenosis over all evaluable segments). Plaque composition was classified 
as noncalcified, mixed, or calcified. Coronary artery calcium (CAC) was quantified using the Agatston method.
Results. Total plaque increased in 48% of patients, and progression was predicted by older age, higher cumu-
lative inflammation, and total prednisone dose (P < 0.05). CAC progressors were older, more obese, hypertensive, 
and had higher cumulative inflammation compared to nonprogressors (P < 0.05). Longer exposure to biologics was 
associated with lower likelihood of noncalcified plaque progression, lesion remodeling, and constrained CAC change 
in patients without baseline calcification, independent of inflammation, prednisone dose, or statin exposure (all 
P < 0.05). Longer statin treatment further restricted noncalcified plaque progression and attenuated the effect of 
 inflammation on increased plaque and CAC (P < 0.05). Stringent systolic blood pressure (BP) control further weak-
ened the effect of inflammation on total plaque progression.
Conclusion. Inflammation was a consistent and independent predictor of coronary atherosclerosis progression 
in RA. It should therefore be specifically targeted toward mitigating cardiovascular risk. Biologic disease- modifying 
antirheumatic drugs, statins, and BP control may further constrain plaque progression directly or indirectly.
INTRODUCTION
Individuals with rheumatoid arthritis (RA) experience a higher 
rate of cardiovascular (CV) events compared to controls (1). We 
recently reported greater prevalence, severity, burden, and vulner-
ability of occult coronary plaque in patients with RA compared 
to age- and sex- matched individuals without autoimmunity (2). 
Increasing atherosclerosis burden on serial coronary computed 
tomography (CT) angiography is an independent predictor of 
acute coronary syndromes in both men and women without auto-
immune disease (3,4). In contrast, stabilization in plaque size is 
associated with decreased risk of future CV events (5). Changes 
in coronary plaque load and composition in RA are largely unex-
plored. Two recent studies evaluated determinants of incident 
coronary artery calcium (CAC) or prevalent CAC progression and 
described associations with age, higher blood pressure (BP), and 
triglyceride levels but not with disease- specific traits or treatments 
(6,7). However, CAC represents ~20% of total plaque burden both 
in patients with RA and in a general patient population, and may 
not be present in earlier disease (2,8). More importantly, having 
additional information on plaque burden and on stenotic severity 
and composition exclusively obtained by coronary CT angiogra-
phy significantly improves upon predictive value of CAC for CV 
events in a general patient population (9).
In the present study, we explored incident coronary plaque 
rates, prevalent atherosclerosis progression, and changes in 
plaque composition in patients with RA who underwent coronary 
CT angiography at baseline and follow- up. We further identified 
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determinants of increasing plaque and CAC burden, and specifi-
cally investigated the role of cumulative inflammation, cardiac risk 
factors, RA- specific or ancillary medications, and their interac-
tions on plaque progression. We hypothesized that higher cumu-
lative inflammation may predict greater coronary plaque load at 
follow- up, and we further posited that duration of exposure to 
RA- specific medications such as glucocorticoids, conventional 
synthetic and biologic disease- modifying antirheumatic drugs 
(DMARDs), traditional cardiac risk factors, and statin treatments 
may exert opposing effects on plaque growth or composition.
PATIENTS AND METHODS
Patient recruitment. One hundred one patients who 
participated in a prior coronary CT angiography study of sub-
clinical coronary atherosclerosis in RA (2) underwent follow- up 
assessments after a mean ± SD of 83 ± 3.6 months. Participants 
were prospectively followed up at our outpatient rheumatology 
clinic since their baseline visit (2010–2011). Inclusion and exclu-
sion criteria have been previously described in detail (2). Briefly, 
patients were enrolled if they met the 2010 American College of 
Rheumatology/European League Against Rheumatism (EULAR) 
classification criteria for RA (10), were ≥18 years of age, and had 
no symptoms or history of CV disease at baseline. Major exclu-
sion criteria were concomitant autoimmune syndromes (with the 
exception of Sjögren’s syndrome), weight >325 pounds (147.7 kg), 
iodine allergy, glomerular filtration rate <60 ml/minute, malignancy, 
and chronic or active infections. The study was approved by the 
local institutional review board, and all participants provided written 
informed consent in accordance with the Declaration of Helsinki.
Predictor variables. Hypertension was defined as a sys-
tolic BP of ≥140 mm Hg or a diastolic BP of ≥90 mm Hg, or the use 
of an antihypertensive agent. Diabetes mellitus was defined as a 
glycosylated hemoglobin level of >6.5% or hypoglycemic medica-
tion use. Hyperlipidemia was defined as a fasting cholesterol level 
of >200 mg/dl, a low- density lipoprotein (LDL) level of >130 mg/dl, 
or statin use. Smoking was defined as cigarette consumption 
within 30 days from screening. The waist- to- height ratio was used 
to measure LDL central obesity (11). Screening for incident cardiac 
risk factors was conducted in accordance with the EULAR recom-
mendations for CV risk assessment (12). Disease activity was eval-
uated using the Disease Activity Score in 28 joints (13) using the 
C- reactive protein level (DAS28- CRP) at every clinic visit. Cumu-
lative inflammatory burden was calculated as a time- averaged 
CRP spanning all visits between baseline and  follow- up scans (14). 
Medications were reconciled at every clinic visit, including use and 
doses of prednisone, conventional synthetic disease- modifying 
antirheumatic drugs (csDMARDs), biologic DMARDs, and statins. 
Total prednisone and methotrexate doses from baseline to follow- 
up were calculated, and the number of years of exposure to bio-
logic DMARDs and statins were also estimated.
Laboratory evaluations. A complete blood cell count, 
comprehensive metabolic panels, erythrocyte sedimentation rate 
(ESR), and CRP levels were calculated on the day of each coro-
nary CT angiography assessment, as well as at every clinic visit 
between scans. Fasting lipid evaluations were performed on the 
day of each scan, in accordance with the EULAR recommenda-
tions for CV risk assessment between scans (12).
Multidetector coronary CT angiography. Baseline scans 
were performed using a 64- multidetector row LightSpeed VCT 
scanner (GE Healthcare) between March 2010 and March 2011. 
Follow- up scans were performed using a 256- multidetector row 
scanner between March 2017 and March 2018. Baseline and 
follow- up images were analyzed in the same campaign and in 
random order by a single, blinded interpreter (MJB) (15). CAC 
was quantified by the Agatston method (16). Coronary arteries 
were evaluated on contrast- enhanced scans using a standard-
ized 17- segment American Heart Association model (17). For 
longitudinal comparisons, baseline and follow- up coronary seg-
ments were coaligned using fixed anatomic landmarks as fidu-
cial points. Each segment was scored for stenosis severity on a 
0–4 scale based on grade of luminal restriction, where 0 = 0% 
(absence of plaque), 1 = 1–29% stenosis, 2 = 30–49% stenosis, 
3 = 50–69% stenosis, and 4 = >70% stenosis (2). Plaque compo-
sition was defined as noncalcified, mixed, or calcified as previously 
reported (18). Subjects received 2 individual quantitative scores; 
the segment involvement score represented the total number of 
segments with plaque, and the segment stenosis score described 
the cumulative stenosis grade rendered by plaque in all evaluable 
segments. Reproducibility of these scoring measures at our insti-
tution has been previously reported (18).
Outcome measures. Changes in burden of total plaque, 
specific plaque types (noncalcified, mixed, and calcified), and 
CAC constituted the primary outcome measures. Atheroscle-
rosis progression was defined as the number of new segments 
with any plaque per patient (segment involvement score increase, 
possible range 0–17) or rise in stenotic plaque severity in all eval-
uable coronary segments with plaque (segment stenosis score 
increase, possible range 0–68). CAC progression was expressed 
as the absolute difference between the follow- up measurement 
and the baseline measurement of CAC.
Statistical analysis. Continuous variables were expressed 
as the mean ± SD, and categorical variables were expressed as 
the number and percentage. Negative binomial regression was 
used to assess continuous outcome measures (segment involve-
ment score increase and segment stenosis score increase), robust 
logistic regression was used to assess categorical outcome meas-
ures (noncalcified, mixed, and calcified plaque progression), and 
generalized linear models with a Tweedie (Poisson- Gamma) error 
distribution and log link function were used to assess CAC change. 
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For each outcome measure, univariable models with candidate 
predictors were estimated, followed by multivariable models con-
structed via a backward elimination variable selection process. The 
backward selection process started with all predictors associated 
with the outcome in univariable analyses at a P value of < 0.20 and 
sequentially removed variables with a P value of >0.10, beginning 
with the least significant variable. For primary outcome measures, 
the possible presence of interactions between cumulative inflam-
mation and traditional risk factors was tested by introducing into the 
adjusted multivariable models the product of time- averaged CRP 
and each CV risk factor, and the product of time- averaged CRP and 
each medication exposure variable. Age and time between scans 
were included as covariates in all models. Odds ratios (ORs) with 
95% confidence intervals (95% CIs) were calculated. Analyses were 
performed using SPSS software.
RESULTS
Participants were predominantly female with estab lished, 
seropositive, erosive, and well- controlled disease (Table 1). Follow- 
 up included an average of 19 visits over 7 years. Forty- eight 
patients were considered plaque progressors based on either 
Table 1. Baseline clinical characteristics of progressors versus nonprogressors*
No plaque progression 
(n = 53)
Plaque progression 
(n = 48)
Total sample 
(n = 101)
Age, years 48.07 ± 9.88 55.19 ± 9.49† 51.45 ± 10.29
Female, no. (%) 46 (86.79) 41 (85.42) 87 (86.14)
Follow- up duration, years 7.00 ± 0.33 6.94 ± 0.34 6.97 ± 0.33
No. of visits 18.83 ± 3.49 18.46 ± 4.18 18.65 ± 3.82
RA- related parameters
RA duration, years 9.18 ± 6.28 11.36 ± 7.98 10.22 ± 7.19
RF- positive, no. (%) 48 (90.57) 43 (89.58) 91 (90.10)
ACPA- positive, no. (%) 47 (88.68) 40 (83.33) 87 (86.14)
Erosions, no. (%) 33 (62.26) 31 (64.58) 64 (63.37)
Time- averaged CRP, mg/dl 0.79 ± 0.53 0.99 ± 1.16 0.89 ± 0.89
Time- averaged SJC 1.83 ± 1.92 2.40 ± 2.84 2.10 ± 2.41
Time- averaged DAS28- CRP 2.69 ± 0.80 2.70 ± 0.90 2.69 ± 0.84
Cardiovascular risk factors
Hypertension at baseline, no. (%) 16 (30.19) 29 (60.42)† 45 (44.55)
Time- averaged systolic BP, mm Hg 127.83 ± 13.11 133.08 ± 11.41† 130.32 ± 12.55
Time- averaged diastolic BP, mm Hg 71.97 ± 7.05 72.21 ± 6.56 72.08 ± 6.79
Dyslipidemia at baseline, no. (%) 25 (47.17) 26 (54.17) 51 (50.50)
Time- averaged LDL, mg/dl 101.78 ± 23.38 109.84 ± 35.30 105.61 ± 29.77
Diabetes at baseline, no. (%) 5 (9.43) 9 (18.75) 14 (13.86)
Current smoking, no. (%) 4 (7.55) 4 (8.33) 8 (7.92)
Waist- to- height ratio 57.82 ± 6.83 61.20 ± 7.78† 59.42 ± 7.46
Medication at baseline
Prednisone use, no. (%) 12 (22.64) 19 (39.58) 31 (30.69)
No. of concomitant csDMARDs 1.90 ± 0.78 1.87 ± 0.79 1.89 ± 0.78
Biologic DMARD use, no. (%) 34 (64.15) 30 (62.50) 64 (63.37)
Statin use at baseline, no. (%) 20 (37.74) 21 (43.75) 41 (40.59)
Medication during follow- up
Cumulative prednisone, gm‡ 2.34 ± 4.49 4.12 ± 6.35 3.19 ± 5.50
Cumulative methotrexate, gm 36.01 ± 18.04 38.81 ± 18.52 37.34 ± 18.23
Biologic DMARD duration, years§ 4.36 ± 2.88 4.24 ± 3.01 4.30 ± 2.93
Statin duration, years¶ 1.83 ± 2.58 3.04 ± 2.82† 2.41 ± 2.75
Baseline plaque burden
Total segment involvement score 0.94 ± 0.97 2.88 ± 2.76† 1.86 ± 2.24
Total segment stenosis score 1.04 ± 1.11 4.46 ± 5.11† 2.66 ± 3.98
Noncalcified plaque >0, no. (%) 29 (54.72) 31 (64.58) 60 (59.41)
Mixed plaque >0, no. (%) 4 (7.55) 20 (41.67)† 24 (23.76)
Calcified plaque >0, no. (%) 3 (5.66) 16 (33.33)† 19 (18.81)
CAC >0, no. (%) 5 (9.43) 26 (54.17)† 31 (30.69)
Agatston score 8.85 ± 53.49 135.29 ± 397.36† 68.94 ± 282.35
* Except where indicated otherwise, values are the mean ± SD. RA = rheumatoid arthritis; RF = rheumatoid factor; ACPA = anti–
citrullinated protein antibody; CRP = C- reactive protein; SJC = swollen joint count; DAS28 = Disease Activity Score in 28 joints; 
BP = blood pressure; LDL = low- density lipoprotein; csDMARDs = conventional synthetic disease- modifying antirheumatic drugs; 
CAC = coronary artery calcium. 
† P < 0.05 versus nonprogressors. 
‡ Patients (n = 49) exposed to prednisone at any time between baseline and follow- up scans. 
§ Patients (n = 78) exposed to biologic DMARDs at any time between baseline and follow- up scans. 
¶ Patients (n = 59) exposed to statins at any time between baseline and follow- up scans. 
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displaying new coronary segments with plaque (segment involve-
ment score change, range 0–6 among all patients) or increased 
stenotic severity in segments with prior plaque (segment stenosis 
score change, range 0–9 among all patients). Clinical characteris-
tics of progressors and nonprogressors are presented in Table 1. 
RA- related parameters and treatments were similarly distributed 
across both groups, including use of csDMARDs, time receiving 
biologic DMARDs, and total prednisone and methotrexate doses. 
Although progressors were older, more obese, more likely to have 
hypertension, and had a higher time- averaged systolic BP com-
pared to nonprogressors, those differences were no longer sig-
nificant after adjustment for age. Progressors more commonly 
had plaque and CAC, as well as higher plaque and CAC scores 
at baseline (P < 0.05). Eight incident CV events (4 ischemic and 
4 nonischemic) occurred throughout the observation period (see 
Supplementary Table 1, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41122/ 
abstract). All patients with CV events remained in the study and 
were included in the analysis.
Incident plaque rates, plaque progression, and cal-
cification over time. Seventy patients (69.3%) displayed cor-
onary plaque at baseline. The rate of incident plaque (segment 
involvement score >0 at follow- up in patients with a baseline 
segment involvement score of 0), was 4.7/100 person- years 
(95% CI 2.2–8.6); in patients with prevalent atherosclerosis 
(baseline segment involvement score >0), plaque progressed at 
a rate of 7.8/100 person- years (95% CI 5.5–10.7). The rate of 
CAC progression was 6.0/100 person- years (95% CI 4.3–8.1); 
it increased at a median of 15.1 Agatston units/year in patients 
with prevalent CAC (95% CI 9.3–32.6). Patients with incident 
CAC demonstrated a median annualized progression rate of 1.7 
units (95% CI 0.8–4.1). Quantitative changes for total plaque 
as well as all 3 plaque subtypes are shown in Supplementary 
Table 2 (available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41122/ abstract). 
Overall, total plaque burden and coronary calcification scores 
increased (P ≤ 0.012); additionally, progression of noncalcified 
plaque occurred in 9 patients, mixed plaque in 21, and calcified 
plaque in 35.
Changes in coronary plaque composition. At base-
line, 187 coronary segments with plaque were identified in 70 
patients. At follow- up, 97 new lesions appeared in segments with-
out plaque initially; 15 new plaques were identified in 10 patients 
(9.9%) without plaque at baseline, while 82 new plaques were 
identified in 37 patients (36.6%) with prevalent plaque. Of the 97 
incident plaques reported at follow- up, 20 were noncalcified, 21 
were mixed, and 56 were calcified. Figure 1 delineates per- plaque 
composition changes from baseline to follow- up.
Figure 1. Change in plaque composition, new plaque (NP), and disappearing plaque (DP) from baseline to follow- up. NCP = noncalcified 
plaque; MP = mixed plaque; CP = calcified plaque.
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Determinants of change in coronary atherosclero-
sis burden. Older age, higher time- averaged CRP, and greater 
total prednisone dose independently predicted both seg-
ment involvement score increase and segment stenosis score 
increase in multivariate models (Table  2). The effect of time- 
averaged CRP on total plaque increase was modified by statin 
use, since time- averaged CRP predicted segment involvement 
score increase only in patients who were not exposed to statins 
Table 2. Predictors of total coronary plaque progression in patients with rheumatoid arthritis*
Segment involvement score 
increase, estimate (95% CI)
Segment stenosis score increase,  
estimate (95% CI)
CAC increase,  
estimate (95% CI)
Univariable 
model
Multivariable 
model
Univariable  
model
Multivariable 
model
Univariable 
model
Multivariable 
model
Age, years – 1.06 (1.03–1.09)† – 1.05 (1.02–1.08)‡ – 1.17 (1.09–1.26)†
Male sex 1.05 (0.38–2.90) – 1.04 (0.43–2.52) – 1.05 (0.38–2.90) –
Hypertension 1.74 (0.92–3.31)§ – 1.61 (0.90–2.90) – 2.54 (1.19–5.42)‡ 2.58 (0.99–6.78)§
Dyslipidemia 0.74 (0.41–1.33) – 0.94 (0.54–1.62) – 1.17 (0.59–2.32) –
Diabetes 1.06 (0.45–2.51) – 1.36 (0.63–2.94) – 0.96 (0.39–2.37) –
Waist- to- height ratio 1.03 (1.00–1.07)§ – 1.02 (0.98–1.06) – 1.07 (1.03–1.11)‡ 1.17 (1.02–1.34)¶
Time- averaged CRP, 
mg/dl
1.64 (1.36–1.98)† 1.42 (1.13–1.78)‡ 1.52 (1.23–1.88)† 1.35 (1.08–1.70)‡ 1.65 (1.34- 2.03)† 1.64 (1.14–2.35)‡
Statin duration, 
years
1.05 (0.95–1.16) – 1.04 (0.94–1.15) – 1.14 (1.03–1.26)‡ –
Biologic DMARD 
duration, years
1.05 (0.97–1.14) – 1.03 (0.94–1.12) – 1.09 (0.96–1.23) –
Cumulative 
methotrexate, gm
1.01 (0.99–1.02) – 1.00 (0.99–1.02) – 1.01 (0.99–1.03) –
Cumulative 
prednisone, gm
1.09 (1.05–1.13)† 1.06 (1.02–1.10)‡ 1.08 (1.05–1.12)† 1.06 (1.02–1.10)‡ 1.07 (1.04–1.11)† 1.10 (1.01–1.21)¶
* 95% = 95% confidence interval; CAC = coronary artery calcium; CRP = C- reactive protein; DMARD = disease- modifying antirheumatic drug. 
† P < 0.001. 
‡ P < 0.01. 
§ P < 0.1. 
¶ P < 0.05. 
Figure  2. Duration of statin exposure and blood pressure control moderate the effect of cumulative inflammation on coronary plaque 
progression in rheumatoid arthritis. Relative risks (RRs) and odds ratios (ORs), with 95% confidence intervals (95% CIs), were calculated. 
A, Higher time- averaged C- reactive protein (CRP) yielded significant plaque progression in patients not receiving statins (RR 1.48 [95% CI 
1.05–2.09], P = 0.025) and those receiving statins for <50% of the study period (RR 1.31 [95% CI 1.01–1.69], P = 0.040). No such risk was 
observed in patients with statin exposure for >50% of the study period (RR 1.07 [95% CI 0.93–1.22], P = 0.35, P for interaction = 0.017). 
B, Higher time- averaged CRP rendered high coronary artery calcium (CAC) progression risk in statin-naïve patients (OR 2.33 [95% CI 1.29–
4.22], P = 0.005); in contrast, any statin exposure mitigated that risk (OR 1.17 [95% CI 0.81–1.68], P = 0.410; P = 0.98 for statin exposure 
<50% and OR 0.96 [95% CI 0.44–2.17], P = 0.98 for statin exposure >50%; P for interaction = 0.006). Both statin interaction models reported in 
A and B are adjusted for age, dyslipidemia, cumulative prednisone dose, total methotrexate dose, and biologic disease- modifying antirheumatic 
drug treatment duration. C, Higher time- averaged CRP significantly predicted CAC progression in patients in the middle and highest tertiles 
of time- averaged systolic blood pressure (TA- SBP) (OR 1.68 [95% CI 1.14–2.47], P = 0.009 and OR 2.39 [95% CI 1.52–3.77], P < 0.001, 
respectively), but not those in the lowest tertile (OR 1.03 [95% CI 0.61–1.74], P = 0.92). SIS = segment involvement score.
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or received statins for <50% of the study period, but not in those 
who received statins >50% of the time (P for interaction = 0.017) 
(Figure 2A).
CAC change was independently predicted by age, obesity, 
time- averaged CRP, and total prednisone dose (Table 2). Statin 
exposure also modified the effect of time- averaged CRP on CAC 
change. Specifically, higher time- averaged CRP was significantly 
associated with CAC change only in patients not exposed to stat-
ins, but not in patients who had any statin exposure during the 
study period (P for interaction = 0.006) (Figure 2B). Additionally, 
the effect of time- averaged CRP on CAC change was moder-
ated by time- averaged systolic BP; specifically, time- averaged 
CRP significantly predicted CAC change in patients in the middle 
tertile (time- averaged systolic BP 126–137 mm Hg) and highest 
tertile (time- averaged systolic BP ≥138 mm Hg), but not those in 
the lowest tertile of time- averaged systolic BP (P for interaction = 
0.023) (Figure 2C).
CAC change was further assessed separately in patients 
with and those without detectable baseline CAC in a supple-
mentary analysis, due to a significant interaction between 
baseline CAC and duration of biologic DMARD treatment (P for 
interaction = 0.001). In a model with adjustment for age, obesity, 
time- averaged CRP, and total prednisone dose, longer biologic 
DMARD exposure was negatively associated with CAC change 
in patients without CAC at baseline (OR 0.77 [95% CI 0.60–
0.98]; P = 0.031), but not in those with prevalent CAC (OR 1.08 
[95% CI 0.94–1.23]; P = 0.28). The presence of CAC at baseline 
did not modify the effects of the other primary predictors on CAC 
change (data not shown).
Determinants of plaque progression by subtype (noncalcified, 
mixed, calcified) are displayed in Table 3. Both a longer duration 
of biologic DMARD treatment and exposure to statins were inde-
pendently associated with a decreased likelihood of noncalcified 
plaque progression. Inclusion of total prednisone and methotrex-
ate dose in the model did not affect the results (data not shown). 
Older age was associated with both mixed plaque and calcified 
plaque progression. Increased calcified plaque burden was further 
associated with obesity and higher cumulative inflammation. 
DISCUSSION
This is the first study to explore predictors of coronary plaque 
progression in a well- characterized, prospective cohort of patients 
with RA without known CV disease and with long- term follow- up. 
We specifically investigated the effects of cumulative inflammation, 
traditional cardiac risk factors, RA- specific and ancillary therapies 
and their interactions on total plaque progression, various plaque 
subtypes, and coronary calcification. Our findings complement 
previous reports on CAC progression in RA (6,7).
We report several novel findings. First, higher cumulative 
inflammation was a consistent and independent predictor of 
total coronary plaque progression in RA. This included new seg-
ments with plaque at follow- up, as well as greater stenosis sever-
ity in segments with plaque at baseline. This is consis tent with 2 
previous studies showing that higher inflammatory burden was 
associated with carotid plaque progression in RA (19,20). How-
ever, our observation is of unique significance, since the pres-
ence of carotid plaque in inflammatory joint  diseases (including 
Table 3. Predictors of change in atherosclerosis burden by plaque type in patients with rheumatoid arthritis*
Noncalcified plaque progression,  
OR (95% CI)
Mixed plaque progression,  
OR (95% CI)
Calcified plaque progression,  
OR (95% CI)
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
Age, years – 1.00 (0.93–1.07) – 1.06 (1.00–1.12)† – 1.18 (1.09–1.27)‡
Male sex 1.17 (0.18–7.73) – 1.34 (0.39–4.59) – 1.78 (0.28–11.23) –
Hypertension 0.25 (0.03–2.11) – 1.68 (0.56–5.02) – 4.30 (1.55–11.96)§ 3.53 (1.00–12.53)¶
Dyslipidemia 0.40 (0.09–1.88) – 0.50 (0.17–1.43) – 1.49 (0.56–3.95) –
Diabetes 0.72 (0.07–7.18) – 1.36 (0.36–5.17) – 2.42 (0.81–7.27) –
Waist- height ratio 0.92 (0.82–1.04) – 1.06 (0.99–1.13) – 1.15 (1.08–1.22)‡ 1.16 (1.07–1.25)‡
Time- averaged CRP, 
mg/dl
1.09 (0.64–1.87) – 0.70 (0.24–2.02) – 3.12 (1.92–5.05)‡ 3.42 (1.85–6.35)‡
Statin duration, years 0.69 (0.55–0.88)§ 0.72 (0.57–0.90)§ 1.14 (0.94–1.39) – 1.10 (0.93–1.31) –
Biologic DMARD 
duration, years 
0.76 (0.60–0.96)† 0.77 (0.61–0.98)† 1.12 (0.93–1.34) – 1.07 (0.92–1.25) –
Cumulative  
methotrexate, gm
1.03 (0.99–1.08) – 1.01 (0.98–1.04) – 1.00 (0.97–1.03) –
Cumulative pred-
nisone, gm
0.99 (0.92–1.07) – 1.05 (0.96–1.13) – 1.08 (0.99–1.18)¶ –
* Model 1 was adjusted for age and time between scans. Model 2 was adjusted as in model 1, and additionally for all variables in the final 
multivariable model selected using backward selection. OR = odds ratio; 95% CI = 95% confidence interval; CRP = C- reactive protein; DMARD = 
disease- modifying antirheumatic drug. 
† P < 0.05. 
‡ P < 0.001. 
§ P < 0.01. 
¶ P < 0.1. 
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RA) does not sufficiently identify patients with coronary artery 
disease and since quantitative measurements of carotid ather-
osclerosis do not correlate with the presence or burden of cor-
onary plaque (21). We used time- averaged CRP as a surrogate 
for cumulative inflammation; in supplementary analyses, similar 
results were observed using time- averaged swollen joint counts 
as a predictor, but not when time- averaged tender joint counts, 
time- averaged patient global assessments, or composite indi-
ces such as the DAS28- CRP or the Clinical Disease Activity 
Index (22) were used. Importantly, higher cumulative inflamma-
tion in RA has been associated with a greater risk of a future 
CV event (23), while reduction in time- averaged inflammation 
yielded a lower risk of a CV event (24). Since ath ero sclerosis 
progression on serial coronary CT angiography independently 
predicted CV events in a general patient population (3,5), our 
observations collectively reaffirm that stringent and durable con-
trol of inflammation should be a primary objective in the quest to 
mitigate CV risk in RA.
Second, higher cumulative inflammation may also promote 
plaque remodeling and maturation, as evidenced by its strong 
association with CAC and calcified plaque progression. Indeed, 
56 of 117 segments (48%) with calcified plaque at follow- up had 
no plaque at baseline. Ostensibly, incident plaques appeared in 
those segments as noncalcified plaques that grew and matured 
over periods of inflammation during disease flares; as inflam-
mation subsided, they eventually transitioned to advanced, 
heavily calcified plaques. Support for this timeline was pro-
vided by supplementary analyses, where we demonstrated 
that the within- patient variability in CRP over time significantly 
predicted CAC progression independent of age, hypertension, 
obesity, and baseline CAC (P = 0.018). In accordance with this, 
previous reports confirmed that early atherogenesis inflam-
mation drives and colocalizes with initial intimal calcification 
(25). In response to proinflammatory cytokine production by 
macrophages at sites of lipid accumulation, vascular smooth 
muscle cells (VSMCs) undergo apoptosis, release extracellular 
vesicles secondary to stress, or undergo phenotype transition 
to osteoblastic cells as a self- preservation strategy. All those 
events are associated with local calcification, which is initially 
undetectable using coronary CT angiography (25). If inflamma-
tion persists, macrophage infiltration and microcalcifications 
progress, eventually appearing as spotty calcifications on cor-
onary CT angiography. If inflammation subsides and the VSMC 
repair system is not overwhelmed (cells do not die by apoptosis 
in the meantime), this process will lead to the development of 
calcified acellular plaque.
In advanced plaque, large, dense calcifications are spatially 
distinct from macrophages, inversely correlate with macrophage 
burden, and—like the calcific mummification of soft tissue infec-
tions—represent healing that stabilizes the arterial wall (25). 
Hence, higher burden of calcified plaque at follow- up may reflect 
the final stage in the plaque life cycle that appeared and evolved 
in the context of a historically higher inflammatory load. However, 
this association between inflammation and calcification was not 
observed in prior studies of CAC progression in RA (6,7). Poten-
tial explanations may be the longer duration of follow- up (7 years 
compared to ≤3 years) and greater number of evaluation points 
(19 compared to 2 or 3) in our study, allowing for a more com-
prehensive assessment of inflammation variability as well as ade-
quate time for plaque remodeling.
Our third novel finding is that longer biologic DMARD expo-
sure may yield an atheroprotective effect in RA, independent of 
stringent control of systemic inflammation. Specifically, lengthier 
biologic DMARD treatment reduced the likelihood of noncalcified 
plaque progression, the earliest histologic atherosclerotic lesion 
discernible on coronary CT angiography. Biologic therapies were 
similarly shown to selectively influence lipid- rich, soft plaque vol-
ume in patients with psoriasis (26). Moreover, we showed that 
lengthier biologic DMARD exposure appeared to prevent matura-
tion and remodeling of such plaques, as evidenced by the lower 
risk of progressive calcification independent of  inflammation, 
duration of statin exposure, and total prednisone dose. In a 
similar manner, biologic DMARDs have been shown to inhibit 
 radiographic progression in RA regardless of attainment of optimal 
disease control (27–29). In contrast, neither duration of exposure 
to csDMARDs nor total methotrexate dose in our study influenced 
coronary plaque progression.
Fourth, we established an independent coronary atheropro-
tective effect of statins in RA. Longer statin exposure was associ-
ated with lower risk of noncalcified plaque progression regardless 
of cumulative inflammation, total prednisone and methotrexate 
dose, or biologic DMARD duration. Indeed, stabilization or reduc-
tion in plaque size, particularly the noncalcified lipid core com-
ponent, is well documented in response to high intensity statin 
therapy in general patient populations (30–33) and related to lower 
risk of CV events (5). However, the atheroprotective effect of statin 
in our study was not related to the treatment intensity, but rather 
the duration of the exposure. Our additional observation that the 
duration of statin exposure moderated the effect of cumulative 
inflammation on both plaque and CAC progression highlights 
potential local antiinflammatory effects of statins at the plaque 
level (34), independent of systemic inflammation as reflected by 
blood CRP levels (35).
Regrettably, sustained remission may be unrealistic for the 
majority of patients at the present time (36). Could RA- specific or 
other ancillary treatments mitigate coronary plaque progression 
in subjects who do not achieve stringent inflammation control? 
We observed that longer statin exposure also moderated the 
effect of inflammation on total plaque progression. In patients 
treated with statins for >50% of the observation time, higher 
time- averaged CRP failed to yield significant progression of 
either coronary plaque or CAC. We further noted that durable, 
aggressive systolic BP control throughout the observation period 
may be instrumental, particularly in the setting of chronic  residual 
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inflammation. Time- averaged systolic BP at the lowest tertile 
(<126 mm Hg) attenuated the effect of higher cumulative inflam-
mation on CAC progression, whereas higher measurements 
significantly accelerated it. Nevertheless, it is presently unclear 
whether atheroprotection in RA—specifically in the context of 
residual inflammation—requires adjustment of the recommenda-
tions for starting lipid- lowering therapy or adoption of more rigor-
ous systolic BP targets than in general patient populations (37).
We also demonstrated that cumulative prednisone dose 
adversely affected total coronary plaque as well as CAC pro-
gression, independent of cumulative inflammation or cardiac risk 
factors. Despite the fact that physicians generally prescribe glu-
cocorticoids to patients with higher disease activity, our observa-
tions highlight the true deleterious effect of glucocorticoids on the 
vascular wall, rather than confounding by indication. Importantly, 
the duration of statin exposure in our study did not moderate the 
effect of total prednisone dose on coronary plaque progression, 
as previously reported for carotid atherosclerosis (19). Since a 
higher cumulative prednisone dose has been linked to a greater 
incidence of CV events in RA (38), timely tapering and withdrawal 
may be warranted.
Our study has certain limitations. First, the absence of a con-
trol group hinders the ability to determine whether the observed 
magnitude and predictors of plaque change in RA are different from 
those in subjects without autoimmunity. However, at least for CAC, 
where there is a precedent for comparison (39), the observed CAC 
progression in our patients was significantly higher than predicted 
based on age, sex, and ethnicity- matched reference values (rela-
tive risk 2.21 [95% CI 1.39–3.52], P = 0.001). Second, our patients 
had low cumulative inflammatory burden; 47% had a time- averaged 
DAS28- CRP of <2.4, and 68% had a DAS28- CRP of <2.8. More-
over, all patients received rigorous screening and management of 
incident cardiac risk factors during their clinic visits. Additionally, 
patients with prevalent calcification or significant plaque burden on 
baseline coronary CT angiography received at least statin therapy, if 
not more aggressive treatment, for atherosclerosis, regardless of the 
presence or absence of clinical symptoms. Consequently, the like-
lihood of plaque progression may have been attenuated in patients 
who would otherwise have exhibited the greatest increase. Accord-
ingly, the proportions, magnitude of plaque progression, and effect 
sizes of predictors may have been attenuated, compared to cohorts 
with higher disease activity or untreated risk factors.
Occult coronary atherosclerosis burden increased in a sig-
nificant proportion of patients with RA. Cumulative inflamma-
tory burden and total prednisone dose were disease- specific, 
independent determinants of plaque progression. Our findings 
confirm the importance of prioritizing and targeting durable control 
of inflammation in RA. Longer exposure to biologic DMARDs or 
statins, as well as rigorous control of systolic BP, may further mod-
erate the effect of inflammation on atherosclerosis  progression 
and yield additional coronary atheroprotective effects beyond 
optimal control of systemic inflammation.
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